科研之友
微信
新浪微博
Facebook
分享链接
摘要
Breast cancer (BrCA) risk stratification using clinico-pathological biomarkers helps improve disease prognosis prediction. However, disease recurrence rates remain unfavorable and individualized clinical management strategies are needed. Consequently, we evaluated the influence of 14 sequence variants detected in IL-10, TGF-beta 1, VEGF, and their associated receptors as effective predictors of BrCA clinical outcomes. Tumor DNA samples collected from 441 BrCA patients were genotyped using TaqMan-PCR. Most selected targets alter cytokine serum/plasma levels or signaling pathways. Relationships between genetic profiles and recurrence as well as disease-related mortality were evaluated using cumulative incidence curves and competing risk regression models. The VEGF C-2578 allele was associated with a 1.3- to 1.6-fold increase in BrCA recurrence (HRtrend = 1.28; 95% CI = 0.96-1.72) and disease-related mortality (HRtrend = 1.56; 95% CI = 0.93-2.56). Although this marker was marginally significant relative to BrCA outcomes, there were substantial gains in the 5- and 8-year predictive accuracy compared to standard prognostic indicators. Among ER+/PR+ status patients, there was a significant impact of the VEGF -2578CC genotype on disease recurrence and predictive accuracy. Our findings suggest inheritance of the VEGF C-2578 allele could serve as an independent prognostic indicator of BrCA prognosis. The VEGF (-2578) marker may have clinical implications among a subset of ER+/PR+ patients with an aggressive phenotype. Because the VEGF C-2578 allele is linked to high VEGF expression, this cytokine is a potential prognostic and targeted clinical management tool.
- 出版日期2010-10
